RAGE: A Multiligand Receptor Contributing to the Cellular Response in Diabetic Vasculopathy and Inflammation

 

 Buy Article Permissions and Reprints

ABSTRACT

RAGE is a multiligand member of the immunoglobulin superfamily of cell surface molecules whose properties extend the paradigm of ligand-receptor interactions. The receptor recognizes families of ligands with diverse structural features, such as advanced glycation endproducts (AGEs), amyloidogenic peptides/polypeptides, amphoterins, and S100/calgranulins rather than individual species. Engagement of RAGE by its ligands upregulates the receptor and initiates a cycle of sustained cellular perturbation; increased levels of RAGE on the cell surface make it an ideal target for subsequent ligand interactions and for propagating cellular dysfunction. At this time, the only means known to break this apparently vicious cycle appears to be blocking access to RAGE or removing the ligands. Taken together, these data suggest that RAGE has the potential to function as a progression factor in a range of disorders (AGEs are relevant to diabetes and other settings of oxidant stress, amyloidogenic peptides are relevant to amyloidoses, S100/calgranulins are relevant to inflammatory disorders, etc.) in which its ligands accumulate. The chronic juxtaposition of ligand and receptor triggers sustained cellular perturbation favoring mechanisms eventuating in tissue injury rather than those that would restore homeostasis.

REFERENCES

• 1 Ruderman N, Williamson J, Brownlee M. Glucose and diabetic vascular disease.  FASEB J . 1992;  6 2905-2914
  PubMedGoogle Scholar
• 2 Baynes J. Role of oxidative stress in development of complications in diabetes.  Diabetes . 1991;  40 405-412
  CrossrefPubMedGoogle Scholar
• 3 Sell D, Monnier V M. Structure elucidation of senescence cross-link from human extracellular matrix: Implication of pentoses in the aging process.  J Biol Chem . 1989;  264 21597-21602
  PubMedGoogle Scholar
• 4 Brownlee M. Advanced glycosylation in diabetes and aging.  Annu Rev Med . 1995;  46 223-234
  CrossrefPubMedGoogle Scholar
• 5 Dyer D, Dunn J, Thorpe S. Accumulation of Maillard products in skin collagen in diabetes and aging.  J Clin Invest . 1993;  91 2463-2469
  CrossrefPubMedGoogle Scholar
• 6 Reddy S, Bichler J, Wells-Knecht K, Thorpe S, Baynes J. Carboxymethyllysine is a dominant AGE antigen in tissue proteins.  Biochemistry . 1995;  34 10872-10878
  CrossrefPubMedGoogle Scholar
• 7 Sell D, Lapolla A, Odetti P, Fogarty J, Monnier V M. Pentosidine formation in skin correlates with severity of complications in individuals with longstanding IDDM.  Diabetes . 1992;  41 1286-1292
  PubMedGoogle Scholar
• 8 Schmidt A M, Vianna M, Gerlach M. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface.  J Biol Chem . 1992;  267 14987-14997
  PubMedGoogle Scholar
• 9 Schmidt A-M, Yan S-D, Wautier J-L, Stern D M. Activation of RAGE: A mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis.  Circ Res . 1999;  84 489-497
  CrossrefPubMedGoogle Scholar
• 10 Neeper M, Schmidt A M, Brett J. Cloning and expression of RAGE: A cell surface receptor for advanced glycosylation end products of proteins.  J Biol Chem . 1992;  267 14998-15004
  PubMedGoogle Scholar
• 11 Kislinger T, Fu C, Qu W. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression.  J Biol Chem . 1999;  274 31740-31749
  CrossrefPubMedGoogle Scholar
• 12 Hensley K, Carney J, Mattson M. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease.  Proc Natl Acad Sci USA . 1994;  91 3270-3274
  PubMedGoogle Scholar
• 13 Hofmann M, Drury S, Caifeng F. RAGE mediates a novel proinflammatory axis: The cell surface receptor for S100/calgranulin polypeptides.  Cell . 1999;  97 889-901
  CrossrefPubMedGoogle Scholar
• 14 Lander H, Tauras J, Ogiste J, Moss R, Schmidt A M. Activation of RAGE triggers a MAP kinase pathway regulated by oxidant stress.  J Biol Chem . 1997;  272 17810-17814
  CrossrefPubMedGoogle Scholar
• 15 Hori O, Brett J, Nagashima M. RAGE is a cellular binding site for amphoterin: Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system.  J Biol Chem . 1995;  270 25752-25761
  CrossrefPubMedGoogle Scholar
• 16 Yan S-D, Chen X, Chen M. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease.  Nature . 1996;  382 685-691
  CrossrefPubMedGoogle Scholar
• 17 Li J, Schmidt A-M. Characterization and functional analysis of the promoter of RAGE.  J Biol Chem . 1997;  272 16498-16506
  CrossrefPubMedGoogle Scholar
• 18 Li J, Qu W, Schmidt A-M. Sp1 binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells.  J Biol Chem . 1998;  273 30870-30878
  CrossrefPubMedGoogle Scholar
• 19 Brett J, Schmidt A-M, Zou Y-S. Tissue distribution of the receptor for advanced glycation endproducts (RAGE): Expression in smooth muscle, cardiac myocytes, and neural tissue in addition to vasculature.  Am J Pathol . 1993;  143 1699-1712
  PubMedGoogle Scholar
• 20 Ritthaler U, Roth H, Bierhaus A. Expression of RAGE in peripheral occlusive vascular disease.  Am J Pathol . 1995;  146 688-694
  PubMedGoogle Scholar
• 21 Schmidt A-M, Yan S-D, Stern D M. The dark side of glucose.  Nature Med . 1995;  1 1002-1004
  PubMedGoogle Scholar
• 22 Herz J, Willnow T. Lipoprotein and receptor interactions in vivo.  Curr Opin Lipidol . 1995;  6 97-103
  PubMedGoogle Scholar
• 23 King G L, Brownlee M. The cellular and molecular mechanisms of diabetic complications.  Endocrinol Metab Clin North Am . 1996;  25 255-270
  CrossrefPubMedGoogle Scholar
• 24 Williamson J, Chang K, Tilton R. Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozotocin-induced diabetes.  Diabetes . 1987;  36 813-821
  PubMedGoogle Scholar
• 25 Wautier J L, Wautier M P, Schmidt A M. AGEs on the surface of diabetic red cells bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications.  Proc Natl Acad Sci USA . 1994;  91 7742-7746
  PubMedGoogle Scholar
• 26 Wautier J L, Zoukourian C, Chappey O. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble RAGE blocks hyperpermeability.  J Clin Invest . 1996;  97 238-243
  CrossrefPubMedGoogle Scholar
• 27 Park L, Raman K, Lee K. Suppression of accelerated diabetic atherosclerosis by soluble receptor for AGE (sRAGE).  Nature Med . 1998;  4 1025-1031
  CrossrefPubMedGoogle Scholar
• 28 Rauvala H, Merenmies J, Pihlaskari R. The adhesive and neurite-promoting molecule p30: Analysis of the amino terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons.  J Cell Biol . 1987;  107 2293-2305
  PubMedGoogle Scholar
• 29 Rauvala H, Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons.  J Biol Chem . 1987;  262 16625-16635
  PubMedGoogle Scholar
• 30 Selinfreund R, Barger S, Pledger W, Van Eldik L. Neurotrophic protein S-100B stimulates glial cell proliferation.  Proc Natl Acad Sci USA . 1991;  88 3554-3558
  PubMedGoogle Scholar
• 31 Newton R, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils.  J Immunol . 1998;  160 1427-1433
  PubMedGoogle Scholar
• 32 Sheng J, Mrak R, Rovnaghi C. Human brain S100 beta and S100 beta mRNA expression increases with age: Pathogenic implications for Alzheimer's disease.  Neurobiol Aging . 1996;  17 359-363
  CrossrefPubMedGoogle Scholar